Abstract

Replication-competent adenovirus type 5 (Ad5) vectors promise to be more efficient gene delivery vehicles than their replication-deficient counterparts, and chimeric Ad5 vectors that are capable of targeting CD46 are more effective than Ad5 vectors with native fibers. Although several strategies have been used to improve gene transduction and oncolysis, either by modifying their tropism or enhancing their replication capacity, some tumor cells are still relatively refractory to infection by chimeric Ad5. The oncolytic effects of the vectors are apparent in certain tumors but not in others. Here, we report the biological and oncolytic profiles of a replication-competent adenovirus 11p vector (RCAd11pGFP) in colon carcinoma cells. CD46 was abundantly expressed in all cells studied; however, the transduction efficiency of RCAd11pGFP varied. RCAd11pGFP efficiently transduced HT-29, HCT-8, and LS174T cells, but it transduced T84 cells, derived from a colon cancer metastasis in the lung, less efficiently. Interestingly, RCAd11p replicated more rapidly in the T84 cells than in HCT-8 and LS174T cells and as rapidly as in HT-29 cells. Cell toxicity and proliferation assays indicated that RCAd11pGFP had the highest cell-killing activities in HT29 and T84 cells, the latter of which also expressed the highest levels of glycoproteins of the carcinoma embryonic antigen (CEA) family. In vivo experiments showed significant growth inhibition of T84 and HT-29 tumors in xenograft mice treated with either RCAd11pGFP or Ad11pwt compared to untreated controls. Thus, RCAd11pGFP has a potent cytotoxic effect on colon carcinoma cells.

Highlights

  • IntroductionThe five-year survival rate is about 50% [1]

  • Colon carcinoma is the second most common malignancy in humans after lung cancer

  • adenovirus type 5 (Ad5) showed a lower degree of infectivity of the LS174T and HCT-8 cell lines compared to species B adenoviruses 24 h p.i

Read more

Summary

Introduction

The five-year survival rate is about 50% [1]. Survival rates are directly linked to how early the cancer is diagnosed, and they have not improved significantly over the past 40 years, despite advances in treatment [2]. Most adult patients are already immune to the commonly used adenovirus serotype, Ad5; as a consequence, a high dose of vector is required for effective treatment [8]. Strategies to circumvent these limitations have involved the use of other adenovirus types that have a better capacity to replicate in vivo

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call